Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...

Alongside record profits, USDT issuer Tether also reported Friday it now holds over $143 billion in reserve assets to back ...

Tether Holdings Ltd., the stablecoin issuer that was pulled into the spotlight this week during the confirmation hearing for ...

All else equal, this would increase gasoline prices, which in most of the country have averaged $3 per gallon for the past ...

Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...

In a report released yesterday, Brett Knoblauch from Cantor Fitzgerald maintained a Buy rating on Cipher Mining (CIFR – Research Report), with ...

Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The ...

KoBold is part of something called the Disko-Nuussuaq project, a mining effort to drill for minerals along Greenland’s ...

We recently published a list of 10 AI Stocks on Latest News and Ratings. In this article, we are going to take a look at ...

Interest in Bitcoin-backed lending is rising right as traditional finance giants see their regulatory barrier fading with the ...

Howard Lutnick, chairman and CEO of investment firms Cantor Fitzgerald and BGC Group, told the U.S. Senate Committee on ...

Billionaire financier Howard Lutnick, President Donald Trump's choice to lead the Commerce Department, said Wednesday that he ...